Soft tissue sarcoma in adults

Current Opinion in Oncology

Volumn 11, Issue 4, 1999, Pages 285-295

  Dirix, Luc Y ^a   Van Oosterom, Allan T ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

CELL CYCLE; CELL PROLIFERATION; HUMAN; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOFT TISSUE SARCOMA;

ADULT; CHROMOSOME ABERRATIONS; HUMANS; SARCOMA; SOFT TISSUE NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033034861     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199907000-00008     Document Type: Review

References (66)

1. 1 McClain KL, Leach CT, Jenson HB, Joshi VV, Ploock BH, Parmley RT, DiCarlo FJ, Chadwick EG, Murphy SB: Association of Epstoin-Barr virus with leiomyosarcomas in young people with AIDS. N Engl J Med 1995, 332:12-18.
2. 2 Fizazi K, Feuillard J, Le Cesne A, Terrier P, Raphael M, Pouillart P, Tursz T: Soft tissue sarcomas in HIV-infected adult patients. Eur J Cancer 1996, 32A; 1812-1814.
3. 3 Kogevinas M, Kauppinen T, Winkelmann R, Becher H, Bertazzi PA, Buenode-Mesquita HB, et al.: Soft tissue sarcoma and non-Hodgkin's lymphoma in workers exposed to phenoxy herbicides, chlorophenols, and dioxins: Two nested case-control studies. Epidemiology 1995, 6:396-402.
4. 4 Lynge E: Cancer incidence in Danish phenoxy herbicide workers, 1847-1993. Environ Health Perspect 1998, 106(suppl 2):683-688. In this Danish cohort study, the manufacturing of phenoxyherbicides was associated with an increased risk of sott tissue sarcoma development.
5. 5 Hardell L, Eriksson M, Degerman A: Meta-analysis of four Swedish case-control studies on exposure to pesticides as risk-factor for soft tissue sarcoma including the relation to tumour localization and histological type. Int J Oncol 1995, 6:847-851.
6. 6 Kramarova E, Kogevinas M, Thuyet Ahn C, Dingh Cau H, Cao Dao L, Stellman SD, Parkin DM: Exposure to agent orange and occurence of soft tissue sarcomas or non-Hodgkin lymphomas: an ongoing study in Vietnam, Environ Health Ferspect 1998, 106(suppl 2); 671-678. The impact of TCDD, one of the most toxic manmade chemicals, as a contaminant of Agent Orange on the incidence of soft tissue sarcomas and non-Hodgkin lymphoma in Vietnam is being investigated. This report indicates the stategy used to study this impact of that exposure in Vietnam. The use of an index reflecting geographical exposure will be compared to biological measurement of herbicides in both tissue and serum.
7. 7 Jensen V, Hoyer M, Sorensen FB, Keller J, Jensen OM. MIB-1 expression and iododeoxyuridine labelling in soft tissue sarcomas: an immunohistochemical study including correlations with p53, bcl-2 and histological characteristics. Histopathology 1996, 28:437-444.
8. 8 Jensen V, Brandt Sorensen F, Bentzen SM, Ladekarl M, Steen Nielsen O, Keller J, Jensen OM: Proliferate activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade sott tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas. Histopathology 1998, 32:536-546. Histopathologic grading is known to be important in the assessment of prognosis in STS. In this study the estimation of proliferative activity was shown to yield significant prognostic information within the group of high-grade sarcomas. The exclusion of MFH-type sarcomas within this high-grade group of tumors again seems to point to significant biological differences between the different sarcoma histiotypes.
9. 9 Choong PFM, Akerman M, Willen H, et al.: Expression of proliferating cell nuclear antigen and Ki67 in soft tissue sarcoma. Is prognostic significance histiotype specific? APMIS 1995, 103:797-805.
10. 10 Drobnjak M, Latres E, Pollack D, Karpeh M, Dudas M, Woodruff JM, et al.: Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas. J Natl Cancer Inst 1994, 86:549-554.
11. 11 Heslin MJ, Carlos-Cardo C, Lewis JJ, Woodruff JM, Brennan MF: Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma. Cancer 1998, 83:490-497. This study confirms the prognostic value of proliferative activity in sarcomas of the high-grade group. Essentially this study confirms the study by Jensen.
12. 12 Huuhtanen RL, Blomqvist CP, Wiklund TA, Virolainen MJ, Elomaa AE, Pan Y, Tribukait B: S-Phase fraction in 155 soft tissue sarcomas. Cancer 1996, 77:1815-1822.
13. 13 Gustafson P, Fernǒ M, Äkerman M, Baldertorp B, Willién H, Killander D, Rydholm A: Flow cytometric S-phase fraction in soft tissue sarcoma: prognostic importance analysed in 160 patients. Brit J Cancer 1997, 75:94-100.
14. 14 Collin F, Chassevent A, Bonichon F, Bertrand G, Terier P, Coindre JM and the FNCLCC sarcoma group: Flow cytometric DNA content analysis of 185 soft tissue neoplasms indicates that S phase fraction is a prognostic factor for sarcomas. Cancer 1997, 79:2371-2379.
15. 15 Shimamura A, Fisher DE: p53 in life and death. Clin Cancer Res 1996, 2:435-440.
16. 16 Würl P, Taubert H, Meye A, Berger D, Lautenschläger Ch, Holzhausen H-J, et al.: Prognostic value of immunohistochemistry for p53 in primary soft tissue sarcomas: a multivariafe analysis of five antibodies. J Cancer Res Clin Oncol 1997, 123:502-508.
17. 17 Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, et al: Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994, 54:794-799.
18. 18 Mousses S, McAuley L, Bell RS, Kandel R, Andrulis IL: Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas. Mod Pathol 1996, 9:1-6.
19. 19 Yoo J, Lee H-K, Kang C-S, Park W-S, Lee J-Y, Shim S-I: p53 gene mutations and p53 protein expression in human soft tissue sarcomas. Arch Pathol Lab Med 1997, 121:395-399.
20. 20 Schneider-Stock R, Radig K, Oda Y, Mellin W, Rys J, Niezabitowski A, Roessner A: p53 gene mutations in soft-tissue sarcomas correlations with p53 immunohistochemistry and DNA ploidy. J Cancer Res Clin Oncol 1997, 123:211-218.
21. 21 Taubert H, Würl P, Bache M, Meye A, Berger D, Holzhausen HJ, et al.: The p53 gene in soft tissue sarcomas: prognostic value of DNA sequencing versus immunohistochemistry. Anticancer Res 1998, 18:183-187.
22. 22 Würl P, Meye A, Schmidt H, Lautenschlager C, Kalthoff H, Rath FW, Taubert H: High prognostic significance of mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. Oncogene 1998, 16:1183-1185.
23. 23 Pollock R, Lang A, Ge T, Sun D, Tan M, Yu D: Wild-type p53 and a p53 temperature-sensitive mutant suppress human soft tissue sarcoma by enhancing cell cycle control. Clin Cancer Res 1998, 4:1985-1994. With the use of a human-derived p53-mutated leiomyosarcoma cell line, the impact of transfection with wild type p53 was evaluated both in-vitro and in-vivo. These studies suggest that restoration of wild type P53 protein expression results in decreased proliferative activity and increased cell cycle control. These data suggest that restoration of p53 might be a reasonable target for sarcoma treatment.
24. 24 Meye A, Würl P, Hinze R, Berger D, Bache M, Schmidt H, et al.: No p161NK4A/CDKN2/MTS1 mutations independent of p53 Status in soft tissue sarcomas. J Pathol 1998, 184:14-17. In 74 mesodermaf tumors no p16 mutation was observed with PCR-SSCP sequencing.
25. 25 Yao J, Pollock RE, Lang A, Tan M, Pisters PWR, Goodrich D, et al.: Infrequent mutations of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma. Clin Cancer Res 1998, 4:1065-1070. The p16 gene was examined in 30 sarcomas, and only one tumor showed rearrangement of this gene.
26. 26 Orlow I, Drobnjak M, Zhang Z-F, Lewis J, Woodruff JM, Brennan MF, Cordon-Cardo C: Alterations of INK4A and INK4B genes in adult soft tisue sarcomas: effect on survival. J Natl Cancer Inst 1999, 91:73-9.
27. 27 Hirakawa N, Naka T, Yamamoto I, Fukuda T, Tsuneyoshi M: Overexpression of bcl-2 protein in synovial sarcoma. Hum Pathol 1996, 27:1060-1065.
28. 28 Suster S, Fisher C, Moran CA: Expression of bcl-2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surfaces, and gastrointestinal tract. Am J Surg Pathol 1998, 22:863-872. Increased bcl-2 protein expression in synovial sarcomas is confirmed in this study.
29. 29 Ahlen J, Larsson O, Enberg U, Brosjö O, Bäckdahl M: EMMPRIN and MMP-2 mRNA are coexpressed in soft tissue sarcoma. Proc AACR 1998, Abstr # 3494, p 505.
30. 30 Hu M, Nicolson GL, Ellis LM, Bucana CB, Pollock RE. Establishment and characterization of tumorigenic, metastatic and angiogenic properties of recently-isolated human sarcoma cells (abstract). Proc AACR 1998, 3852:567.
31. 31 Saenz NC, Heslin MJ, Adsay V, Lewis JL, Leung DH, LaQuaglia MP, Brennan MF: Neo-vascularity and clinical outcome in high-grade soft tissue sarcomas. Ann Surg Oncol 1998, 5:48-53.
32. 32 Benassi MS, Ragazzini P, Gamberi G, Sollazzo MR, Molendini L, Ferrari C: Adhesion molecules in high-grade soft tissue sarcomas: correlation with clinical outcome. Eur J Cancer 1998, 34:496-502. This study shows the importance of the extracellular matrix as an essential and specific component of tumor growth and development. Sarcoma histiotype-specific integrin expression is recognized, and the prognostic importance of laminin receptor is analyzed in soft tissue sarcomas.
33. 33 Mohamed AN, Zalupski MM, Ryan JR, Koppitch F, Balcerzak S, Kempf R, Wolman SR: Cyto-genetic aberrations and DNA ploidy in soft tissue sarcoma. Cancer Genet Cytogenet 1997, 99:45-53.
34. 34 Forus A, Berner J-M, Meza-Zepeda LA, Saeter G, Mischke D, Fodstad Ø, Myklebost O : Molecular characterization of a novel amplicon at 1q21-q22 freqently observed in human sarcomas. Brit J Cancer 1998, 78:495-503.
35. 35 Mertens F, Fletcher CDM, Dal Cin P, De Wever I, Mandahl N, Mitelkman F, Rosai J, Rydholm A, Sciot R, Tallini G, Van den Berghe H, Vanni R, Willen H: Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP study group. Genes Chromosomes Cancer 1998, 22:16-25. In 46 pleomorphic soft tissue sarcomas no specific cytogenetic aberration could be identified.
36. 36 Plaat BEC, Muntinghe FLH, Molenaar WM, Hoekstra HJ, Bosveld HEP, Dam A, Dijkhuizen T, Van Den Berg E : Clinical outcome of previously untreated soft tissue sarcomas in relation to tumor grade, DMA ploidy and karyotype. Int J Cancer 1997,745:396-402.
37. 37 Panicek DM, Go SD, Healy JH, Leung DHY, Brennan MF, Lewis JJ. Soft-tissue sarcoma in-volving bone or neurovascular structures:MR imaging prognostic factors. Radiology 1997, 205:871-875
38. 38 Heslin MJ, Lewis JJ, Woodruff JM, Brennan MF. Core needle biopsy for diagnosis of extremity soft tissue sarcoma. Ann Surgical Oncol 1997, 4:425-431.
39. 39 Nieweg OE, Pruim J, van Ginkel RJ, Hoekstra HJ, Paans AMJ, Molenaar WM, Schraffordt Koops H, Vaalburg W: Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996, 37:257-261.
40. 40 van Ginkel RJ, Hoekstra HJ, Pruim J, Nieweg OE, Molenaar WM, Paans AMJ, Willemsen ATM, Vaalburg W, Schraffordt Koops H: FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma. J Nucl Med 1996, 37: 984-990.
41. 41 Jones DN, McCowage GB, Sostman HD, Brizel DM, Layfield L, Charles HC, Dewhirst MW, Prescott DM, Friedman HS, Harrelson JM, Scully SP, Coleman RE: Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med 1996, 37:1438-1444.
42. 42 Lucas JD, O'Doherty MJ, Wong JCH, Bingharn JB, McKee PH, Fletcher CDM, Smith MA : Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft tissue sarcomas. J Bone Joint Surg 1998,80-B:441-447. 62 patients with STS were assessed both by FDG-PET and with MRI for local recurrence and CT scan for lung metastases. PET scanning clearly has the advantage of a one time whole body assessment , but both MRI and CT had better sensitivity scores for respectively local recurrence and lung metastases detection.
43. 43 Pisters PWT, Leung DHY, Woodruff J, Shi W, Brennan MF: Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996, 14:1679-1689.
44. 44 Heslin MJ, Woodruff J, Brennan MF: Prognostic significance of a positive microscopic margin in high-risk extremity soft tissue sarcoma: implications for management. J Clin Oncol 1996, 14:473-478.
45. 45 Lewis JJ, Leung D, Heslin M, Woodruff JM, Brennan MF. Association between local recurrence and subsequent survival in extremity soft tissue sarcoma. J Clin Oncol 1982, 15:646-652.
46. 46 Goodlad JR, Fletcher CDM, Smith MA: Surgical resection of primary soft-tissue sarcoma. Incidence of residual tumour in 95 patients needing reexcision after local resection. J Bone Joint Surg 1996, 78-B:658-661.
47. 47 Midis GP, Pollock RE, Chen NP, Feig BW, Murphy A, Pollack A, Pistors PWT : Locally recurrent soft tissue sarcoma of the extremities. Surgery 1998, 123:666-671.
48. 48 Rydholm A, Gustafson P, Rööser B, Willen H, Berg NO. Subcutaneous sarcoma. A population based study of 129 patients. J Bone and Joint Surg 1991, 73-B:662-667.
49. 49 Brooks AD, Heslin MJ, Leung DHY, Lewis JJ, Brennan MF. Superficial soft tissue sarcoma: an analysis of prognostic factors. Ann Surg Oncol 1998, 5:41-47.
50. 50 Karakousis CP, De Young C, Driscoll DL: Soft tissue sarcomas of the hand and foot: management and survival. Ann Surgical Oncol 1998, 5:238-240.
51. 51 Eggermont AMM, Schraffordt Koops H, Liénard D, Kroon BBR, van Geel AN, Hoekstra HJ, Lejeune FJ: Isolated limb perfusion with high-dose tumor necrosis factor-a in combination with interferon-g and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996, 14:2653-2665.
52. 52 Gutman M, Inbar M, Lev-Shlush D, Abu-Abid S, Mozes M, Chaitchik S, Meller I, Klausner JM: High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer 1997, 79:1129-1137.
53. 53 Van der Veen AH, Eggermont AMM, Seynhaeve ALB, Van Tiel ST, Ten Hagen TLM: Biodistribution and tumor localization of stealth liposomal tumor necrosis factor-a in soft tissue sarcoma bearing rats. Int J Cancer 1998, 77:901-906.
54. 54 Rüegg C, Yilmaz A, Bielor G, Bamat J, Chaubert P, Lejeune FJ: Evidence for the involvement of endothelial cell integrin avb3 in the disruption of the tumor vasculature induced by TNF and IFN-g. Nature Medicine 1998,4:408-414. The administration of tumor necrosis factor and interferon g results in reduced expression of aVb3 integrin leading to an increased endothelial cell apoptosis. These results offer an explanation for the selective vascular targeting of the isolated limb perfusion therapy with TNF and IFN.
55. 55 Rosenberg SA, Tepper J, Glatstein E, et al. : The treatment of soft-tissue sarcomas of the extremities. Ann Surg 1987, 205:349-359.
56. 56 Brennan MF, Hilaris B, Shiu MH, Lane J, Magill G, Friedrich C, Hajdu SI: Local recurrence in adult soft-tissue sarcoma. A randomized trial of brachytherapy. Arch Surg 1987, 122:1289-93.
57. 57 Harrison LB, Franzese F, Gaynor JJ, Brennan MF: Long-term results of a prospective randomized trial of adjuvant brachytherapy in the management of completely resected soft tissue sarcomas of the extremity and superficial trunk. Int J Radiat Oncol Biol Phys 1993, 27:259-265.
58. 58 Pisters PWT, Harrison LB, Leung DHY, Woodruff J, Casper ES, Brennan MF: Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996, 14:859-868.
59. 59 Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, Delaney T, Glatstein E, Steinberg SM, Merino MJ, Rosenberg SA: Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremities. J Clin Oncol 1998, 16:197-203. This randomized study shows a clear reduction in local recurrence rate in patients treated with limb-sparing surgery. This reduction occured equally in high-and low-grade sarcomas, but in neither group did this result in an overall survival benefit.
60. 60 Alekhteyar KM, Leung DH, Brennazn MF, Harrison LB: The effect of combined external beam radiotherapy and brachytherapy on local control and wound complications in patients with high-grade soft tissue sarcomas of the extremity with positive microscopic margins. Inf J Radiation Oncology Biol Phys 1996, 36: 321-324.
61. 61 Olieman AFT, Pras E, Van Ginkel RJ, Molenaar WM, Koops HS, Hoekstra HJ: Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft tissue sarcoma. Int J Radiat Oncol Biol Phys 1998, 40:807-814.
62. 62 Vrouenraets BC, Keus RB, Nieweg OE, Kroon BB: Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha interferon gamma and melphalan in patients with irresectable soft tissue tumors. J Surg Oncol 1997, 65:88-94.
63. 63 Van Oosterom AT, Krzemienlecki K, Nielsen OS, Judson I, Mouridsen HT, Svancarova L, Woll P, Spooner D, Hermans C, Van Glabbeke M, Verweij J: Final results of a randomized phase II study of the EORTC soft tissue and bone sarcoma (STSBS) group comparing two different ifostamide (IF) regimens in chemotherapy untreated advanced soft tissue sarcoma (STS) patients (pts) (abstract 5520). Ann Oncol 1998, 9(suppl4):115.
64. 64 Frustaci S, Comandone A, Bearz A, Boglione A, Buonadonna A, Stefanovski P, Bumma C : Efficacy and tolerability of an ifosfamide continuous infusion (IFO-C.I.) soft tissue sarcoma (STS) patients (pts) (abstract 1993). Proc ASCO 1998, 518a.
65. 65 Bui NB, Demaille MC, Chevreau C, Blay JY, Cupiossol D, Rios M, et al.: qMAID vs MAID +25% with GCSF in adults with advanced soft tissue sarcomas (STS). First results of a randomized study of the FNCLCC sarcoma group (abstract 1991 ). Proc ASCO 1998, 517a.
66. 66 Sarcoma Meta-analysis Collaboration: Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997, 350:1647-1654.